UP - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources UPUK. For full access, REGISTER.

1 2 3 4 5
hits: 262
1.
  • Immune checkpoint inhibitor... Immune checkpoint inhibitors for hepatocellular carcinoma
    El Dika, Imane; Khalil, Danny N.; Abou‐Alfa, Ghassan K. Cancer, October 1, 2019, Volume: 125, Issue: 19
    Journal Article
    Peer reviewed
    Open access

    The position of immunotherapy as a pillar of systemic cancer treatment has been firmly established over the past decade. Immune checkpoint inhibitors are a welcome option for patients with different ...
Full text

PDF
2.
  • Immunotherapy in hepatocell... Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
    Harding, James J.; Dika, Imane; Abou‐Alfa, Ghassan K. Cancer, February 1, 2016, Volume: 122, Issue: 3
    Journal Article
    Peer reviewed
    Open access

    Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit. Preclinical data have indicated that several ...
Full text

PDF
3.
  • Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
    Abou-Alfa, Ghassan K; Meyer, Tim; Cheng, Ann-Lii ... The New England journal of medicine, 2018-Jul-05, Volume: 379, Issue: 1
    Journal Article
    Peer reviewed
    Open access

    Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the ...
Full text

PDF
4.
  • Pemigatinib for previously ... Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
    Abou-Alfa, Ghassan K; Sahai, Vaibhav; Hollebecque, Antoine ... The lancet oncology, 05/2020, Volume: 21, Issue: 5
    Journal Article
    Peer reviewed
    Open access

    Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. This study ...
Full text

PDF
5.
  • Nivolumab versus sorafenib ... Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
    Yau, Thomas; Park, Joong-Won; Finn, Richard S ... The lancet oncology, January 2022, 2022-01-00, 20220101, 2022-01, Volume: 23, Issue: 1
    Journal Article
    Peer reviewed

    Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1–2 CheckMate 040 study. We aimed to ...
Full text
6.
  • Pertuzumab and trastuzumab ... Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
    Javle, Milind; Borad, Mitesh J; Azad, Nilofer S ... The lancet oncology, September 2021, 2021-09-00, 20210901, Volume: 22, Issue: 9
    Journal Article
    Peer reviewed

    Systemic therapies for metastatic biliary tract cancers are few, and patients have a median overall survival of less than 1 year. MyPathway evaluates the activity of US Food and Drug ...
Full text
7.
  • Equipoise, drug development... Equipoise, drug development, and biliary cancer
    Lee, Tristan Y.; Bates, Susan E.; Abou‐Alfa, Ghassan K. Cancer, March 1, 2022, 2022-03-01, 2022-03-00, 20220301, Volume: 128, Issue: 5
    Journal Article
    Peer reviewed
    Open access

    Current paradigms in emerging treatments encourage clinicians in a position to choose promising, yet unproven, therapies for patients with a lethal disease. This article characterizes the challenge ...
Full text
8.
  • Prospective Genotyping of H... Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
    Harding, James J; Nandakumar, Subhiksha; Armenia, Joshua ... Clinical cancer research, 04/2019, Volume: 25, Issue: 7
    Journal Article
    Peer reviewed
    Open access

    Prior molecular profiling of hepatocellular carcinoma (HCC) has identified actionable findings that may have a role in guiding therapeutic decision-making and clinical trial enrollment. We ...
Full text

PDF
9.
  • Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
    Gordan, John D; Kennedy, Erin B; Abou-Alfa, Ghassan K ... Journal of clinical oncology, 2020-Dec-20, Volume: 38, Issue: 36
    Journal Article
    Peer reviewed

    To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC). ASCO convened an Expert Panel to conduct a ...
Full text
10.
  • Association between posttre... Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma
    Abou‐Alfa, Ghassan K.; Wang, Xiaoliang; Parrinello, Christina M. ... Cancer, 1 July 2023, 2023-Jul-01, 2023-07-00, 20230701, Volume: 129, Issue: 13
    Journal Article
    Peer reviewed
    Open access

    Background Clinical trials suggest α‐fetoprotein (AFP) reduction may be prognostic among patients with advanced hepatocellular carcinoma. However, the association of AFP reduction with outcomes in ...
Full text
1 2 3 4 5
hits: 262

Load filters